文献速递创伤骨科

直接口服抗凝药对澳大利亚和新西兰髋部骨折诊疗的影响:一项前瞻性患者冲刺审计

The impact of direct oral anticoagulants on hip fracture care in Australia and New Zealand: a prospective patient sprint audit.
PubMed 文献 · Osteoporos Int · 2025-08-19

该前瞻性冲刺审计纳入澳大利亚和新西兰髋部骨折登记处(ANZHFR)参与医院中2024年6月1日至7月30日连续收治的≥50岁髋部骨折患者1043例,其中192例(18%)入院时正在服用直接口服抗凝药(DOAC)。与未服用抗血栓药物患者相比,服用DOAC患者手术时间>36小时的比值比为3.65(95%CI 2.40-5.55),服用其他抗血栓药物患者为1.62(95%CI 1.12-2.34);服用DOAC患者手术时间中位数为39小时(IQR 24-48)。作者认为服用DOAC患者可能较未服用抗血栓药物患者经历手术延迟。

要点

  • 1043例髋部骨折患者中192例(18%)入院时服用DOAC。
  • 服用DOAC患者手术时间>36小时的OR为3.65(95%CI 2.40-5.55),高于未服用抗血栓药物患者。
  • 服用DOAC患者手术时间中位数39小时(IQR 24-48),未服用抗血栓药物患者25小时(IQR 20-39)。

核心结论

  • 服用DOAC的髋部骨折患者可能较未服用抗血栓药物患者经历手术延迟,且延迟程度可能超过服用其他抗血栓药物患者所经历的情况。

研究设计与样本

  • 对参与澳大利亚和新西兰髋部骨折登记处(ANZHFR)的医院进行前瞻性冲刺审计。
  • 收集2024年6月1日至7月30日连续收治的≥50岁髋部骨折患者关于DOAC使用、人口学和临床管理的数据。
  • 主要结局为手术时间。

主要发现

  • 1043例髋部骨折患者中192例(18%)入院时服用DOAC。
  • 服用DOAC患者手术时间>36小时的OR为3.65(95%CI 2.40-5.55),服用其他抗血栓药物患者OR为1.62(95%CI 1.12-2.34),均以未服用抗血栓药物患者为参照。
  • 服用DOAC患者手术时间中位数为39小时(IQR 24-48),未服用抗血栓药物患者为25小时(IQR 20-39),服用其他抗血栓药物患者为27小时(IQR 20-44)。
  • 围手术期输血比例在各组间无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Management of hip fracture patients on direct oral anticoagulants in Australia and New Zealand is unclear. Hip fracture patients on DOACs had three times higher odds of time to surgery > 36 h than patients on no antithrombotic medication. Balancing individual considerations and guidelines may shorten time to surgery. PURPOSE: The management of hip fracture patients taking direct oral anticoagulants (DOACs) requires balancing anticoagulation concerns and adherence to recommendations of surgery within 36 h. This study compares the management and time to surgery of hip fracture patients in Australia and New Zealand who were on DOACs, other antithrombotic medication, and no antithrombotic medication. METHOD: A sprint audit of hospitals participating in the Australian and New Zealand Hip Fracture Registry (ANZHFR) was conducted. Sprint audit data regarding DOAC use, demographics, and clinical management was collected for consecutive patients aged ≥ 50 years admitted to hospital with a hip fracture between 1 June and 30 July 2024. The primary outcome was time to surgery. RESULTS: Of 1043 hip fracture patients, 192 (18%) were taking DOACs on presentation to hospital. Patients on DOACs had 3 times higher odds (OR 3.65, 95% CI 2.40-5.55), and patients on other antithrombotic medication had 1.6 times higher odds (OR 1.62, 95% CI 1.12-2.34) of time to surgery > 36 h, compared to patients on no antithrombotic medication. The median time to surgery for patients on DOACs was 39 h (IQR 24-48); for patients on no or other antithrombotic medication, time to surgery was 25 h (IQR 20-39) and 27 h (IQR 20-44), respectively. There were no differences in the proportion of patients who had perioperative blood transfusions. CONCLUSIONS: Patients on DOACs are likely to experience delays to surgery compared to patients on no antithrombotic medication, beyond what patients on other antithrombotic medications may experience.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Wijekulasuriya S, Seymour H, Tarrant S, et al. The impact of direct oral anticoagulants on hip fracture care in Australia and New Zealand: a prospective patient sprint audit. Osteoporos Int. 2025. PMID: 40828478. doi:10.1007/s00198-025-07659-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。